Treace Medical Concepts (TMCI) investor relations material

Strategic overview and market positioning

• Focused on improving surgical outcomes for bunion patients with innovative 3D correction technologies and a dedicated sales team.

• Holds the largest dollar share in the U.S. bunion market, targeting a $5 billion total addressable market with significant under-penetration.

• Expanded from a single Lapiplasty technology to a comprehensive bunion solutions portfolio, now serving all bunion classes.

• Accelerated market penetration by launching new products targeting the high-volume osteotomy segment and arthritic toe procedures.

• Achieved a 21% CAGR in surgeon user growth over five years, reaching over 3,300 active surgeons in 2025.

Product innovation and clinical outcomes

• Lapiplasty 3D procedure offers reproducible, comprehensive correction, supported by strong clinical evidence and broad adoption.

• New Nanoplasty and Percuplasty 3D MIS systems address the minimally invasive trend, reducing pain and recovery time.

• SpeedMTP system targets patients with arthritic great toe, expanding the addressable market.

• Next-generation Lapiplasty Lightning platform to be commercialized in late 2026, promising faster, more accurate procedures.

• IntelliGuide PSI platform enables personalized, preoperative planning and patient-specific surgical guides.

Financial performance and operational efficiency

• Improved adjusted EBITDA by 55% in 2024 and reduced adjusted EBITDA loss by 64% in 2025.

• Reduced cash usage by 46% in 2025 and targeting a further 50% reduction in 2026.

• Secured a new debt facility in late 2025, extending interest-only payments and supporting commercial plans.

• Revenue guidance for 2026 is just above $200 million, with a focus on achieving cash flow independence in the next one to two years.